Nurses play significant role in multidisciplinary management of patients receiving enzalutamide
Role was highlighted in analysis of phase 3 PROSPER trial of enzalutamide in patients with nonmetastatic castration-resistant prostate cancer.
Role was highlighted in analysis of phase 3 PROSPER trial of enzalutamide in patients with nonmetastatic castration-resistant prostate cancer.
“What we need is continued work on integrating surgery and systemic therapy,” says Patrick Kenney, MD.
The FDA is set to have a decision regarding the subcutaneous nivolumab formulation on or by February 28, 2025.
Real-world data showed routine use of darolutamide regimens in community urology practice for patients with metastatic hormone-sensitive prostate cancer.
Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.
Sarah P. Psutka, MD, MSc, shares the rationale for the “Get Moving Trial,” exploring at-home prehabilitation for patients with muscle-invasive bladder cancer.
UGN-101 showed efficacy in a broad population of patients with upper tract urothelial cancer and recurrence-free survival rates were high among patients who responded to…
“So, in the MoonRISe-1 study, we’re studying the efficacy of TAR-210 to prevent recurrence within the bladder by inserting the TAR-210 in the bladder every…
Patients receiving PUL experienced improvements of 8.6 and (39.1%) and 10 (46.8%) in IPSS total score.
There were no adverse events, such as penile bruising, swelling, edema, allergy, or penile fracture, observed in patients treated with shockwave therapy plus platelet rich…
“[The] NURE-Combo trial provided insights into the potential value of expanding chemotherapy combinations with immune checkpoint [inhibitors] in muscle-invasive disease,” said Chiara Mercinelli, MD.